Le coenzyme Q10: biochimie, physiopathologie de sa carence et interet potentiel d'une augmentation de ses apports.

Animals; Cardiovascular Diseases/etiology; Coenzymes; Humans; Parkinson Disease/etiology; Ubiquinone/administration & dosage/analogs & derivatives/chemistry/deficiency/physiology

Abstract :

[en] After a brief reminding of the synthesis and function of coenzyme Q10, this article tries to summarise the current state of knowledge about the consequences of its deficiency and about the potential benefits of an increased intake of this coenzyme. We then describe the arguments in favour of such an increase in cardiac diseases and in Parkinson's disease.

Disciplines :

Pharmacy, pharmacology & toxicology

Author, co-author :

Malchair, P.

Van Overmeire, Lionel ; Centre Hospitalier Universitaire de Liège - CHU > Néphrologie

Boland, André ; Université de Liège - ULiège > Centre d'oncologie

Salmon, Eric ; Centre Hospitalier Universitaire de Liège - CHU > Neurologie Sart Tilman

Pierard, Luc ; Centre Hospitalier Universitaire de Liège - CHU > Cardiologie

Seutin, Vincent ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Pharmacologie

Language :

French

Title :

Le coenzyme Q10: biochimie, physiopathologie de sa carence et interet potentiel d'une augmentation de ses apports.

Alternative titles :

[en] Coenzyme Q10: biochemistry, pathophysiology of its deficiency and potential benefit of an increased intake

Publication date :

2005

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Hopital de Baviere, Liège, Belgium

Volume :

Issue :

Pages :

45-51

Available on ORBi :

since 29 April 2010

Statistics

Number of views

719 (40 by ULiège)

Number of downloads

1923 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Waelkens J.- Statines et coenzyme Q10: bons pour le coeur. Le Généraliste, 2002, 622, 14-16.
Tran MT, Mitchell TM, Kennedy DT et al.- Role of Coenzyme Q10 in chronic heart failure, angina, and hypertension. Pharmacotherapy, 2001, 21, 797-806.
Greenberg S, Frishman WH.- Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol, 1990, 30, 596-608.
Platt R.- Current concepts in optimum nutrition for cardiovascular disease. Prev Cardiol, 2000, 3, 83-87.
Sole MJ, Jeejeebhoy KN.- Conditioned nutritional requirements: therapeutic relevance to heart failure. Herz, 2002, 27, 174-78.
Burke BE, Neuenschwander R, Olson RD.- Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. South Med J, 2001, 94, 1112-17.
Harker-Murray A, Tajik A, Ishikura F et al.- The role of coenzyme Q10 in the pathophysiology and therapy of experimental congestive heart failure in the dog. J Cardiac Failure, 2000, 6, 233-42.
Mortensen SA, Vadhanavikit S, Baandrug U.- Long-term coenzyme Q10 therapy: a major advance in the management of resistant myocardial failure. Drugs Exp Clin Res, 1985, 11, 581-93.
Langsjoen P, Folkers K.- Long-term efficacy and safety of Coenzyme Q10 therapy for idiopathic dilated cadiomyopathy. Am J Cardiol, 1990, 60 (Abstr.), 521.
Morisco C, Trimarco B, Condorelli M.- Effect of coenzyme Q10 in patients with congestive heart failure: a long term multi-center randomized study. Clin Invest, 1993, 71, 134-36.
Soja AM, Mortensen SA.- Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol Asp Med, 1997, 18, S159-S168.
Crestanello JA, Doliba NM, Babsky AM, et al.- Effect of coenzyme Q10 supplementation on mitochondrial function after myocardial ischemia reperfusion. J Surg Res, 2002, 102, 221-28.
Mahley RW, Bersot TP.- Drug therapy for hypercolesterolemia and dyslipidemia. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's The Pharmacological basis of Therapeutics. Mc Graw Hill, 2001, 971-1002
Folkers K, Langsjoen P, Willis R, et al.- Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A, 1990, 22, 8931-34.
Laaksonen R et al.- The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol, 1996, 77, 851-54.
Nakaqhara K, Kuriyama M, Sonoda Y, et al.- Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. Toxicol Appl Pharmacol, 1998, 152, 99-106.
Mizuno Y et al.- Deficiencies in complex I subunits of the respiratory chain in Parkinson's Disease. Bioch Biophys Res Communic, 1989, 163, 1450-55.
Parker WD, Boyson SJ, Parks JK.- Abnormalities of the Electron Transport Chain in Idiopathic Parkinson's Disease. Ann Neurol, 1989, 26, 719-23.
Mann VM, Cooper JM, Krige D, et al.- Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's Disease. Brain, 1992, 115, 333-42.
Betarbet R, Sherer TB, MacKenzie G, et al.- Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neurosci, 2000, 3, 1301-06.
Shults CW et al.- Effects of Coenzyme Q10 in early Parkinson Disease. Arch Neurol, 2002, 59, 1541-50.
Tsuji A, Saheki A, Tamai I, et al.- Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier. J Pharmacol Exp Ther, 1993, 267, 1085-90.
Saheki A, Terasaki T, Tamai I, et al.- In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutamate coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res, 1994, 11, 305-11.
Corsini A, Bellosta S, Baetta R, et al.- New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther, 1999, 84, 413-28.
Caballero J, Nahata M.- Do statins slow down Alzheimer's disease? A review. J Clin Pharm Ther, 2004, 29, 209-13.
Rahman S, Hargreaves I, Clayton P, et al.- Neonatal presentation of coenzyme Q10 deficiency. J Pediatr, 2001, 139, 456-58.
Ferrante RJ et al.- Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci, 2002, 22, 1592-99.
Lodi R et al-. Mitochondrial dysfunction in Friedreich's ataxia: from pathogenesis to treatment perspectives. Free Radic Res, 2002, 36, 461-66.
Rozen TD et al.- Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia, 2002, 22, 137-41.
Lister RE.- An open, pilot study to evaluate the potential benefits of coenzyme. Q10 combined with Ginkgo biloba extract in fibromyalgia syndrome. J Int Med Res, 2002, 30, 195-99.
Van Maldergem L et al.- Coenzyme Q-responsive Leigh's encephalopathy in two sisters. Ann Neurol, 2002, 52, 750-54.
Watts GF, Playford DA, Croft KD, et al.- Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia, 2002, 3, 420.
Lamson DW, Plaza SM.- Mitochondrial factors in the pathogenesis of diabetes: a hypothesis for treatment. Altern Med Rev, 2002, 7, 94-111.
Gazdik F et al.- Decreased levels of coenzyme Q(10) in patients with bronchial asthma. Allergy, 2002, 57, 811-14.